Navigation Links
IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following September Meeting of European Committee for Medicinal Products for Human Use (CHMP)
Date:9/26/2008

IRVINE, Calif., Sept. 26 /PRNewswire-FirstCall/ -- IDM Pharma, Inc. (Nasdaq: IDMI) today announced that it met with representatives of the Committee for Medicinal Products for Human Use (CHMP) and Secretariat of the European Medicines Agency (EMEA) on September 25th, following the CHMP's September meeting where CHMP considered the Company's Marketing Authorization Application (MAA) for mifamurtide (L-MTP-PE) for the treatment of patients with non-metastatic, resectable osteosarcoma, a rare and often fatal bone tumor that typically affects children and young adults.

Based on discussions at that meeting, the Company has been invited to present to the CHMP Scientific Advisory Group on Oncology (SAG-O) and to the CHMP to review and address the remaining open issues in its MAA for L-MTP-PE. These meetings are scheduled to take place in November. The SAG-O is regularly convened at the request of the CHMP to provide independent advice on scientific/technical matters relating to oncology products under evaluation by the CHMP, or on any other scientific issue relevant to the work of the CHMP that relates to this area. The Company will provide SAG-O and CHMP information to address the remaining open issues in advance of these meetings.

"The European review of L-MTP-PE continues to progress," said Timothy P. Walbert, president and chief executive officer, IDM Pharma. "We are pleased to report that, in response to the comprehensive information we submitted in advance of the September CHMP meeting, the CHMP has determined that the Children's Oncology Group's (COG) Phase 3 trial is compliant with Good Clinical Practices (GCP) and that the database from this pivotal study can be reliably used in the evaluation process of the MAA. We also r
'/>"/>

SOURCE IDM Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
2. Lotus Pharmaceuticals, Inc.s New Drug Laevo-Bambutero Begins Evaluation for Clinical Trials
3. VIA Pharmaceuticals Completes Patient Visits in Phase 2 Acute Coronary Syndrome (ACS) Trial
4. QuatRx Pharmaceuticals Announces Additional Data From Phase 3 Study for Ophena(TM) (Ospemifene Tablets) Showing Improvements in Clinical Symptoms of Vulvovaginal Atrophy
5. PharmAthene Presents Data for Protexia(R) and Valortim(R) at 2008 BARDA Industry Conference / PHEMCE Stakeholders Workshop
6. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
7. Oramed Pharmaceuticals Commences Phase 2A Trials of its Oral Insulin Capsule on Type 1 Diabetics
8. Enobia Pharma Appoints Industry Veterans with Commercial and Manufacturing Expertise to Expand Senior Management Team
9. Vion Pharmaceuticals Enters into Agreement to Conduct a Phase I/II Clinical Trial of Cloretazine(R) in Combination with Induction Therapy in Poor Prognosis AML Patients
10. Enobia Pharma Receives FDA Orphan Drug Designation for Hypophosphatasia Product Candidate ENB-0040
11. Pharmasset to Present at the UBS Global Life Sciences Conference on Wednesday, September 24th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... July 28, 2014  Houston dentist , ... offers orthodontic treatment with Invisalign. With access to ... have their teeth straightened without feeling self-conscious in ... associated with other types of braces, but patients ... in addition to better support for their oral ...
(Date:7/28/2014)... 28, 2014 Concord Medical Services Holdings Limited ... ), a leading specialty hospital management solution provider and ... imaging centers in China , today ... Directors declared a special cash dividend of US$0.30 per ... on the Company,s outstanding ordinary shares. The total expense ...
(Date:7/28/2014)...  ANI Pharmaceuticals, Inc. (NASDAQ: ANIP ) ... second quarter and year-to-date 2014 financial results on Monday, ... financial markets. The earnings press release will be accessible ... www.anipharmaceuticals.com . Arthur S. Przybyl ... C. Arnold , Vice President and Chief Financial Officer, ...
Breaking Medicine Technology:Houston Cosmetic Dentist, Dr. Behzad Nazari, Now Offers Orthodontic Treatment with Invisalign 2Concord Medical Declares Special Dividend 2ANI Pharmaceuticals Schedules Conference Call for Second Quarter 2014 Financial Results 2
... Inc. (NASDAQ: MLAB ), a Lakewood, Colorado ... to announce the release of DataTrace Pro (DT Pro) ... and DataTrace RF wireless, real-time data loggers.  From the ... complying with regulatory requirements, DT Pro offers the user ...
... LLC has been awarded an agreement with the Premier ... Premier healthcare alliance for provision of steam sterilization equipment ... is a leading manufacturer of "state of the art" ... negotiated pricing and terms for equipment which can save ...
Cached Medicine Technology:
(Date:7/29/2014)... Los Angeles, CA (PRWEB) July 29, 2014 ... score of 3.1 out of 5. This score reflects ... a result of the large number of suppliers, the ... septic tank market, says IBISWorld analyst Jordan Weinstein. IBISWorld ... provides buyers with a substantial number of supplier options. ...
(Date:7/29/2014)... The Marietta cosmetic dentists at ... for high school and college students heading back to ... whitening is a safe, professional strength system, as the Marietta ... students at these important stages in life. , Many students ... had their teeth whitened. "After braces, teeth can be ...
(Date:7/28/2014)... NAPW honors Pamela ... Center, as a 2014 Professional Woman of the Year. ... leadership in community health. As the largest, most-recognized networking ... industry and profession, the National Association of Professional Women ... 600,000 members and nearly 300 Local Chapters. , In ...
(Date:7/28/2014)... NY (PRWEB) July 28, 2014 Ticket ... the Guinness International Champions Cup Match between Manchester City ... Stadium in the Bronx has hosted countless big events since ... charm and history of the original Yankee Stadium, however, it ... the New York City metro area. , The Yankees ...
(Date:7/28/2014)... 2014 UHY LLP, a member of ... of UHY International Business – Issue 29. This bi-annual ... the most current business challenges and key issues faced ... covers the following topics:, , Key ... thrive over the next five years? Where are growth ...
Breaking Medicine News(10 mins):Health News:Septic Tanks Procurement Category Market Research Report Now Available from IBISWorld 2Health News:Septic Tanks Procurement Category Market Research Report Now Available from IBISWorld 3Health News:Septic Tanks Procurement Category Market Research Report Now Available from IBISWorld 4Health News:Back to School Teeth Whitening Extravaganza For High School Students and Collegiates During August 2014 2Health News:Back to School Teeth Whitening Extravaganza For High School Students and Collegiates During August 2014 3Health News:National Association of Professional Women Announces Pamela A. Schulters, Head Nurse at Kings County Hospital Center, a 2014 Professional Woman of the Year 2Health News:Liverpool FC vs. Manchester City Tickets at Yankee Stadium: Ticket Down Reports Huge Demand for Guinness International Champions Cup Tickets in NYC 2Health News:Liverpool FC vs. Manchester City Tickets at Yankee Stadium: Ticket Down Reports Huge Demand for Guinness International Champions Cup Tickets in NYC 3Health News:Uhy International Business Issue 29 Now Available 2Health News:Uhy International Business Issue 29 Now Available 3
... America s (GSA) latest book features the most comprehensive ... older people. This unique publication includes forward-looking essays by ... articles from GSAs peer-reviewed journals. Civic Engagement in ... multi-year initiative at GSA funded by The ...
... 7, 2010) Three investigators from The Saban Research ... into the prestigious Society for Pediatric Research. Their election ... achievements in pediatrics. The Society for Pediatric ... of investigators engaged in creating new knowledge that advances ...
... , TUESDAY, Dec. 7 (HealthDay News) -- Might technologies and ... help them lose weight? Two agencies at the U.S. ... agencies are co-funding seven clinical trials that will examine how ... other technology to help young people control their weight and, ...
... , TUESDAY, Dec. 7 (HealthDay News) -- Teens ... and often believe their friendships are stronger than they actually ... of 2,060 teens who took part in a 1994-1996 survey ... About two-thirds of the teens rated their health as "excellent" ...
... Larry Ambrose left his bed in the middle of the night ... only able to see three out of the four glowing numbers ... but within days was hospitalized for what was later diagnosed as ... not determine the cause. Cryptogenic stroke, or stroke ...
... December 7, 2010 We,ve all been there: we are watching ... love scene appears. A new study published in Applied ... averting of eyes is normal, especially when you are accompanied ... not all movie-watching experiences are enjoyable or positive. Some movies ...
Cached Medicine News:Health News:New civic engagement resource spotlights boomers, seniors 2Health News:Investigators from Children's Hospital LA honored 2Health News:Co-Opting Technology for the Sake of Weight Loss 2Health News:Teens' Poor Health Linked to Fewer Friends 2Health News:New trial studies link between stroke and atrial fibrillation 2Health News:New trial studies link between stroke and atrial fibrillation 3Health News:Are all movie viewing experiences enjoyable? 2
The Plasmacup SC satisfies two important requirements: high primary stability and a low friction bearing surface....
The cementless biomEx cup can be used with both cemented and cementless femoral stems....
The Secur-Fit cups incorporate enhancements derived from years of clinical, radiographic, and implant retrieval observations....
The Progeny femoral stem offers a cemented option built upon a clinically proven design. Standard and lateralized offsets are available to allow interoperative soft tissue balancing without compromis...
Medicine Products: